{"organizations": [], "uuid": "4ce66645e1518816a9ae5a02cfe0235050424c5b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eyegate-announces-top-line-results/brief-eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery-idUSASB0C3Y4", "country": "US", "domain_rank": 408, "title": "BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T15:49:00.000+02:00", "replies_count": 0, "uuid": "4ce66645e1518816a9ae5a02cfe0235050424c5b"}, "author": "", "url": "https://www.reuters.com/article/brief-eyegate-announces-top-line-results/brief-eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery-idUSASB0C3Y4", "ord_in_thread": 0, "title": "BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery", "locations": [], "entities": {"persons": [{"name": "tri", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "acc", "sentiment": "none"}, {"name": "eyegate pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 5, 2018 / 1:49 PM / in 19 minutes BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery Reuters Staff \nFeb 5 (Reuters) - Eyegate Pharmaceuticals Inc: \n* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY \n* EYEGATE PHARMACEUTICALS INC - IN THE PHASE 2B STUDY, EGP-437 DEMONSTRATED A HIGHER RATE OF SUCCESS COMPARED TO VEHICLE AT ALL TIME POINTS \n* EYEGATE- CO-PRIMARY ENDPOINTS OF SUBJECT PROPORTIONS WITH DAY 7 ACC COUNT 0, SUBJECTS WITH PAIN SCORE 0 AT DAY 1 DIDN‘T SHOW STATISTICAL SIGNIFICANCE​ \n* EYEGATE - ‍EGP-437 SHOWED NUMERICALLY BETTER CLINICAL EFFICACY, DEFINED AS ACC COUNT OF ZERO, THROUGHOUT STUDY, ESPECIALLY AT DAY 14, BEYOND​ \n* EYEGATE - ‍FOR SECONDARY ENDPOINTS, EGP-437 SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN ACC COUNT AND PAIN SCORE, ON DAY 7 AND DAY 1 RESPECTIVELY​ \n* EYEGATE PHARMACEUTICALS INC - ‍EGP-437 ARM DEMONSTRATED A FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS REPORTED​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T15:49:00.000+02:00", "crawled": "2018-02-05T16:12:57.000+02:00", "highlightTitle": ""}